A new trading day began on Friday, with INmune Bio Inc (NASDAQ: INMB) stock price up 3.27% from the previous day of trading, before settling in for the closing price of $2.45. INMB’s price has ranged from $1.89 to $11.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -23.07% over the past five years. Meanwhile, its annual earnings per share averaged 22.20%. With a float of $18.90 million, this company’s outstanding shares have now reached $26.59 million.
Let’s look at the performance matrix of the company that is accounted for 22 employees. In terms of profitability, gross margin is 100.0%, operating margin of -112458.0%, and the pretax margin is -111016.0%.
INmune Bio Inc (INMB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of INmune Bio Inc is 28.90%, while institutional ownership is 21.31%. The most recent insider transaction that took place on Sep 30 ’24, was worth 52,868. In this transaction Chief Financial Officer of this company bought 10,000 shares at a rate of $5.29, taking the stock ownership to the 1,285,869 shares. Before that another transaction happened on Sep 12 ’24, when Company’s President and CEO bought 15,380 for $6.38, making the entire transaction worth $98,048. This insider now owns 1,554,106 shares in total.
INmune Bio Inc (INMB) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.6 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.56% during the next five years compared to -23.07% drop over the previous five years of trading.
INmune Bio Inc (NASDAQ: INMB) Trading Performance Indicators
Here are INmune Bio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1345.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.42 in one year’s time.
Technical Analysis of INmune Bio Inc (INMB)
INmune Bio Inc (NASDAQ: INMB) saw its 5-day average volume 0.7 million, a negative change from its year-to-date volume of 1.58 million. As of the previous 9 days, the stock’s Stochastic %D was 35.68%.
During the past 100 days, INmune Bio Inc’s (INMB) raw stochastic average was set at 6.56%, which indicates a significant decrease from 26.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was lower than the 0.55 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.99, while its 200-day Moving Average is $6.25. Nevertheless, the first resistance level for the watch stands at $2.58 in the near term. At $2.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.71. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.38. The third support level lies at $2.32 if the price breaches the second support level.
INmune Bio Inc (NASDAQ: INMB) Key Stats
With a market capitalization of 67.26 million, the company has a total of 26,585K Shares Outstanding. Currently, annual sales are 10 K while annual income is -42,080 K. The company’s previous quarter sales were 50 K while its latest quarter income was -9,740 K.
